浙江仙琚制药股份有限公司 关于取得去氧孕烯炔雌醇片境内生产药品注册证书的公告

Group 1 - The company has received approval from the National Medical Products Administration for the registration of Deoxymethyltestosterone tablets, which will enhance its gynecological product line and improve market competitiveness [1][3] - The approved product has the same specifications as the original product, containing 0.15 mg of Deoxymethyltestosterone and 20 mcg of Ethinyl Estradiol [2] - The reference formulation for the approved product is Mercilon^[®], which was developed by N.V. Organon and has been marketed in several countries since its launch in 1987 [1][2] Group 2 - The approval of Deoxymethyltestosterone tablets aligns with the company's strategy to expand its product offerings in the gynecological sector [3] - The product is indicated for contraception, which may address a significant market need [1] - The company acknowledges that drug development, production, and sales are subject to uncertainties influenced by national policies and market conditions [3]